KELOWNA, British Columbia, November 9, 2016 /PRNewswire/ --
Marapharm Ventures Inc. ("Marapharm") (OTCQB: MRPHF;CSE: MDM; FSE: 2M0) announces its intentions to shareholders and interested parties on its Nevada operations as a result of the "yes" vote (at press time 9:05pm PST vote was 53.51% in favour) to allow recreational use for marijuana. The "yes" vote supports the proposal to legalize marijuana for recreational use for individuals 21 and over in Nevada.
Linda Sampson, CEO says, "All of our production and cultivation is pre-sold for medical purposes so the 'yes' vote does not affect our present structure but it makes us aggressive for expansion in Nevada in cultivation and distribution for recreational product and we are on the hunt for acquisitions within the space."
ABOUT MARAPHARM VENTURES INC.
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com), the OTC website (http://www.otcmarkets.com) and Sedar website (http://www.sedar.com) under the profile for Marapharm Ventures Inc.
FOR FURTHER INFORMATION:
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.
Contact: email@example.com Telephone: +1-778-583-4476
SOURCE Marapharm Ventures Inc.